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Abstract 
Platelets are blood cells responsible for vascular integrity preservation. The activation of platelet 
receptor CLEC-2 could partially mediate the latter function. Although this receptor is considered to be of 
importance for hemostasis, the rate-limiting steps of CLEC-2 induced platelet activation are not clear. 
Here we aimed to investigate CLEC-2-induced platelet signal transduction using computational 
modelling in combination with experimental approaches. We developed a stochastic 
multicompartmental computational model of CLEC-2 signalling. The model described platelet activation 
beginning with CLEC-2 receptor clustering, followed by Syk and SFK phosphorylation, determined by the 
cluster size. Active Syk mediated LAT protein phosphorylation and membrane signalosome formation, 
which resulted in the activation of Btk, PLC and PI3K, calcium and phosphoinositide signalling. The 
model parameters were assessed from published experimental data. Flow cytometry, TIRF and confocal 
microscopy and western blotting quantification of the protein phosphorylation were used for the 
assessment of the experimental dynamics of CLEC-2-induced platelet activation. Analysis of the model 
revealed that the CLEC-2 receptor clustering leading to the membrane-based signalosome formation is a 
critical element required for the accurate description of the experimental data. Both receptor clustering 
and signalosome formation are among the rate-limiting steps of CLEC-2-mediated platelet activation. In 
agreement with these predictions, the CLEC-2 induced platelet activation, but not activation mediated 
by G-protein coupled receptors, was strongly dependent on temperature conditions and cholesterol 
depletion. Besides, the model predicted that CLEC-2 induced platelet activation results in cytosolic 
calcium spiking, which was confirmed by single platelet TIRF microscopy imaging. Our results suggest a 
refined picture of the platelet signal transduction network associated with CLEC-2. We show that the 
tyrosine kinases activation is not the only rate-limiting step in CLEC-2 induced activation of platelets. 
Translocation of receptor-agonist complexes to the signalling region and LAT-signalosome formation in 
this region are limiting CLEC-2-induced activation as well. 
Statement of significance 
CLEC-2 is a recently discovered platelet receptor implicated in the control of vascular integrity. Here we 
computationally reconstructed the regulation of tyrosine-kinase and calcium signalling network that 
controls blood platelet activation via CLEC-2 receptor. We demonstrated that the assembly of the 
receptors in clusters is the rate-limiting processes in the tyrosine kinase-associated signal transduction, 
which could explain the slow rates of platelet activation by CLEC-2. Additionally, we demonstrated for 
the first time that CLEC-2 stimulation leads to cytosolic calcium spiking, with a qualitative change caused 
by the clustering-affecting influences such as temperature and cholesterol saturation. 
1. Introduction 
The main task of platelets, non-nucleated cellular fragments produced from megakaryocytes in the bone 
marrow, is prevention of the blood loss upon vessel wall disruption (1). Platelets circulate in the 
cardiovascular system for approximately seven days, until they get eliminated in the spleen or liver (2). 
Alongside their primary role in hemostasis, platelets were demonstrated to be involved in angiogenesis 
(3), tissue remodelling (4, 5), and leukocyte recruitment under inflammatory conditions (6, 7). Platelets 
respond gradually to various activators (1). Platelet response to the contact with extracellular matrix 
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protein collagen includes shape change, granule release and, in some cases, cell death (8). In contrast, 
platelet response to ADP includes only shape change and integrin activation  (8). 
There are two main types of signalling pathways in blood platelets, associated either with G-proteins or 
with tyrosine kinase signalling (9). Platelet G-protein coupled receptors (GPCR) govern responses to ADP 
(P2Y1, P2Y12 receptors), thromboxane A2 (TxA2), thrombin (protease-activated receptors 1 and 2 (PAR1, 
PAR4)), epinephrine (α2A) and prostacyclin (IP) (10, 11). Platelet receptors that induce tyrosine kinase 
network of signalling are the receptors for collagen (glycoprotein VI (GPVI)) (8, 12), for IgG (FcγRIIa) (9), 
and recently found on platelets receptor CLEC-2 (C-type lectin-like receptor II-type (CLEC-2)) (8). The 
only confirmed endogenous CLEC-2 ligand is a membrane protein podoplanin, expressed by the 
lymphatic endothelial cells (13, 14). Therefore the primary platelet CLEC-2 physiological function is 
considered to be the separation of blood and lymphatic systems (15–18). Other known CLEC-2 agonists 
are snake venom protein rhodocytin (19, 20), and brown seaweed extract fucoidan (21). CLEC-2 also 
contributes to the maintenance of blood vessel integrity during inflammatory conditions (17, 22–25) and 
has a role in thrombus formation and wound healing (7, 23, 26–29) and in various pathologies (30–32). 
This makes CLEC-2 a prospective therapeutic target (7, 29, 32, 33). Thus, systemic understanding of the 
CLEC-2 signalling is of essential importance. 
A distinct feature observed upon platelet activation via CLEC-2 by either podoplanin, rodocytin or 
fucoidan was 1-2 minute lag-time before activation (21, 34). This has been demonstrated using 
spectrofluorimetric assay of platelet cytosolic calcium (21). However, it is not understood, whether 
platelet CLEC-2 can induce cytosolic calcium spiking, prolonged cytosolic calcium oscillations or transient 
increase of cytosolic calcium. The prolonged platelet CLEC-2 induced response may be a consequence of 
ADP-containing granule secretion and TxA2 synthesis. Another possible cause of the significant 
activation lag-time is the receptor clustering, as was proposed by Pollitt et al. (34). Indeed, glycosylated 
extracellular stalk regions (35), as well as the GxxxG region in the transmembrane domain of CLEC-2 (35, 
36), lead to homodimerisation of the recombinant CLEC-2 proteins (35). On the surface of the resting 
platelets, CLEC-2 is present both in dimeric and monomeric forms (35, 36). Upon ligand binding, CLEC-2 
undergoes multimerisation (36), which might be ligand driven (e.g. tetrameric rhodocytin can bind two 
copies of single CLEC-2, or two CLEC-2 dimers simultaneously (37)). On the other hand, non-multimeric 
podoplanin still induces CLEC-2 cluster formation (38), which implies more complex clustering 
mechanisms. The platelet responses to CLEC-2 are also highly dependent on actin polymerisation and 
cholesterol presence in the plasma membrane (34, 39). However, unlike cholesterol presence, actin 
cytoskeleton reorganization is not required for CLEC-2 oligomerisation (34). Badolia et al. have recently 
reported that CLEC-2 induced signalling is still detectable after the abrogation of secondary activation 
(40).  
Computational modelling approach could be useful to reveal the sequence of events in CLEC-2 induced 
platelet activation and identification of rate-limiting steps in this pathway. Mukherjee et al. 
demonstrated that receptor clustering is significant for the activation of ITAM-bearing receptors (B-cell 
receptors (BCR) and T-cell receptors (TCR)) (41). The significance of platelet receptor clustering was 
demonstrated experimentally for CLEC-2 (38) and GPVI (42), however, the computational models of 
GPVI-induced platelet activation do not incorporate the receptor clustering (43, 44). Due to their small 
size, platelets do not possess significant amounts of signalling proteins. For example, there are only 
2000 copies of phospholipase Cγ2 (PLCγ2) in platelets (approximately 500 nM). Even upon strong 
activation, no more than 25% of signalling proteins become active (44). Thus, it can be claimed that 
there are less than 100 active signal-transducing proteins in platelets upon weak stimulation. Due to low 
amounts of active participants of the signalling cascades in platelets, deterministic modelling might not 
be capable of providing reliable calculation results. Thus, stochastic approaches are required for platelet 
models (45–47).   
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Here we aimed to reveal the primary events of platelet activation upon stimulation through CLEC-2 by 
means of computational modelling and experimental analysis. The proposed in silico model described 
platelet activation starting from ligand binding to CLEC-2 and proceeding until calcium ions release from 
the dense tubular system. The model predicted that besides tyrosine kinase activity, platelet activation 
via CLEC-2 is limited by the CLEC-2 receptor clustering in the plasma membrane, the CLEC-2 clustering 
pattern and the LAT signalosome formation. Model predictions were supported experimentally by an 
essential dependence of CLEC-2-induced platelet activation on temperature and by modulation of 
membrane saturation of cholesterol by methyl-β-Cyclodextrin (mβCD). The model also predicted CLEC-2 
induced calcium spiking, which was confirmed experimentally using total internal reflection microscopy 
(TIRF-microscopy). Our data enable us to propose a refined concept of signal transduction upon platelet 
activation via CLEC-2. 
2. Methods 
Reagents 
The sources of the materials were as follows: calcium-sensitive cell-permeable fluorescent dye Fura-2-
AM, Fura Red-AM (Molecular Probes, Eugene, OR); Fucoidan from Fucus vesiculosis, ADP, PGI2, EGTA, 
HEPES, bovine serum albumin, apyrase grade VII, methyl-β-cyclodextrin (mβCD) (Sigma-Aldrich, St Louis, 
MO). VM-64 antibody was a kind gift of Dr A.V. Mazurov (NMRC of Cardiology, Moscow, RF) (48). 
Blood collection and platelet isolation 
Healthy volunteers, both men and women aged between 18 and 35 years were recruited into the study. 
Investigations were performed under the Declaration of Helsinki and written informed consent was 
obtained from all donors. Blood was collected into 4.5 ml tubes containing 3,8% sodium citrate (1:9 
vol/vol) and supplemented by apyrase (0.1 U/mL). The study was approved by the Independent Ethics 
Committee at CTP PCP RAS (1_2018-1 from 12.01.2018). Platelets were purified by double 
centrifugation as described previously (45, 49). Briefly, platelet-rich plasma was obtained by 
centrifugation at 100 g for 8 minutes. Platelet-rich plasma was supplemented with additional sodium 
citrate (27 mM) and centrifuged at 400 g for 5 minutes. The resultant supernatant was removed and 
platelets resuspended in Tyrode’s buffer (150 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 0.4 mM NaH2PO4, 5 
mM HEPES, 5 mM glucose, 0.2% bovine serum albumin, pH 7.4). Alternatively, blood was collected in Li-
heparin (IMPROVACUTER®) or hirudin (SARSTEDT Monovette®) containing vacuum tubes.  
Flow cytometry and inhibitory analysis 
For continuous flow cytometry experiments, washed platelets were incubated with either 2 μM Fura 
Red-AM (2 μM of Fura-2) before the final wash for 45 minutes at room temperature or for 30 min at 
37OC in the presence of apyrase (1 U/mL). Platelets were then incubated in buffer A for 10 minutes and 
then centrifuged.  Whole blood was incubated with either 2 μM Fura Red-AM (or 2 μM of Fluo-3 or Fluo-
4 and 2 μM of Fura-2) for 30 min at 37OC in the presence of apyrase (1 U/mL). Whole blood was diluted 
20-times with calcium and albumin containing Tyrode’s buffer. Samples were diluted to concentration 
1000 plt/μl and analysed using FACS Canto II or FACS Aria (BD Biosciences, San Jose, CA, USA) flow 
cytometer in a continuous regime with 20s interruption for the addition of an activator.  
Immunoblotting 
Human platelets from drug-free volunteers were prepared on the day of the experiment as described 
previously (50) and suspended in modified Tyrodes-HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 
mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3) to a density of 1.5 × 109 
cells/ml. Stimulation of platelets with 10x fucoidan (final concentration: 1 μg/ml 10 μg/ml, 100 μg/ml), 
was performed for 0-15-30-60-90-120-150-180-300 s at 25 or 37 °C in an aggregometer with continuous 
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stirring (1000 rpm). Reactions were abrogated by addition of 4x SDS-PAGE sample treatment buffer (200 
mM Tris-HCl pH6.8, b-MeEtOH 400 mM, SDS 4%, Bromphenol blue 0.01%, Glycerol 40%). Samples were 
then heated to 99oC for 10 minutes and centrifuged at 15000g for 10 minutes in order to remove cell 
debris. 
Proteins were separated by SDS-PAGE on 10% gels and transferred to polyvinylidene difluoride (PVDF) 
membranes that were then blocked by incubation in 5% (w/v) bovine serum albumin dissolved in TBS-T. 
Primary and secondary antibodies were diluted in TBS-T containing 2% (w/v) bovine serum albumin and 
incubated with PVDF membranes for 1.5 h at room temperature. Blots were washed 4 times for 15 
minutes in TBS-T after each incubation with antibodies and then developed using an enhanced 
chemiluminescence detection system using ECL Prime western blotting detection reagent. Primary 
antibodies were used at a concentration of 1 μg/ml (anti-phosphotyrosine PY20) or diluted 1:1000 (anti-
tubulin). Horseradish peroxidase-conjugated secondary antibodies were diluted 1:1000. In order to 
control for protein loading, membranes were stripped by washing 2 times for 30 minutes in stripping 
buffer (250 mM Glycine, 0.2% SDS, 0.1% Tween-20, pH 2.2) twice for 10 minutes in PBS and 2 times for 5 
minutes in TBST at room temperature. Membranes were then blocked for 30 minutes by 2% TBS-T BSA 
solution at room temperature and re-stained with anti-tubulin antibodies. 
Depletion of platelet cholesterol 
Cholesterol was depleted from the plasma membrane of platelets, by incubation of washed platelets for 
15 minutes with different concentrations of mβCD at 37o C before stimulation as described in (51).  
Immunofluorescent microscopy 
Washed human platelets were activated by Fucoidan (100 μg/ml) at 25oC (with or without cholesterol 
depletion by mβCD) or at 37oC and fixed by 4% PFA after 30, 60, 90, 120, 300 seconds after activation. 
Platelets incubated with CRP (5 μg/ml) or mQ water for 300s were used as positive and negative 
controls, correspondingly. Fixed platelets were washed from PFA by sequential centrifugation, 
resuspended in PBS-BSA buffer and adhered to poly-L-lysine (0.1 % in mQ, Sigma-Aldrich US) covered 
glass coverslips for 90 minutes at 37oC. Non-adherent platelets were removed by gentle rinsing of the 
coverslips. Fixed platelets on the glass were then permeabilised by 0.2% Triton X-100 in the presence of 
2% BSA and 1% Goat serum. After permeabilisation platelets were incubated with 1:250 diluted LAT 
pY1911 (Abcam, US) antibodies for 90 minutes at room temperature. After washing primary antibodies 
off, platelets were incubated with secondary antibodies, conjugated with FITC (Imtek, RF) for 90 minutes 
in the darkroom at room temperature. After washing off secondary antibodies, cells were additionally 
fixed by adding 4% PFA for 10 minutes. Samples were then mounted with Dako fluorescence mounting 
media (Agilent, US). Samples were analyzed by means of Zeiss Axio Observer Z1 microscope (Carl Zeiss, 
Jena, Germany) in the confocal mode.  
Live cell microscopy 
For microscopy experiments, platelets were loaded with calcium fluorophores and immobilised by either 
incubation of platelet suspension in the flow chamber for 5 min, or by perfusing whole blood over the 
surface at a shear rate of 200 s-1 for 5 minutes. For total internal reflection fluorescent (TIRF) 
microscopy, platelets were immobilised either on fucoidan (100 μg/ml) or anti-CD31 (VM-64) (48) and 
investigated in flow chambers (52). An inverted Nikon Eclipse Ti-E microscope equipped with 100x/1.49 
NA TIRF oil objective was used. Cells were observed in DIC and TIRF modes. 405 nm laser was applied to 
assess calcium-free Fura-2 fluorescence in a platelet. Calcium concentration was assessed from Fura-2 
fluorescence as a ratio of initial and running values with taking exponential bleaching of the dye into 




Nikon NIS-Elements software was used for microscope image acquisition; ImageJ 
(http://imagej.net/ImageJ) was used for image processing for both TIRF-microscopy and western 
blotting and microscopy assays from literature. The absolute size of CLEC-2 clusters (Fig. S1D) was 
calculated from the fluorescence intensity, which was assumed to be proportional to the number of 
receptors per cluster. It has also been assumed that only CLEC-2 monomers and dimers are present on 
the surface of resting platelets. Flow cytometry data were processed using FlowJo 
(http://www.flowjo.com/) software. Statistical analysis was performed in Python 3.6. 
Model solution and sensitivity analysis 
The model, formed of ordinary differential equations (see supplement) with initial variable values (Table 
S2, S5, S7) was integrated using the LSODA method in COPASI software. The stochastic model was 
solved using stochastic integration methods (combined Adaptive SSA/the tau-leap method (53, 54)) 
implemented in COPASI software, similarly to previously published methods (45, 55). Parameter 
estimation was performed using Genetic Algorithm. Models are given in the supplement (see Table S9).  
Sensitivity score was calculated as , where  and  represent the model 
output (e.g. the steady-state and time to reach the peak in Syk activity) in respect of the initial 
parameter set (obtained from parameter fitting) and the adapted parameter respectively. 
3. Results 
3.1. Scheme of biochemical reactions underlying our model of CLEC-2-induced platelet activation. 
The model development was carried out based on the known details of the CLEC-2 signalling network. 
Briefly, after binding of CLEC-2 to its ligand, CLEC-2 receptor-ligand complexes rapidly form tight 
clusters, predominantly in the lipid rafts (35, 36). Activated and clustered CLEC-2 molecules can be 
phosphorylated by platelet Syk tyrosine kinases (56). Although it has been proposed that Src family 
kinases (SFK) also participate in the process of CLEC-2 phosphorylation (57, 58), here in the model we 
considered SFK merely as a positive mediator for Syk basal activation (17). The inactive Syk rapidly 
bound two phosphorylated CLEC-2 receptors by two Src homology 2 (SH-2) domains. Association with 
CLEC-2 resulted in Syk activation and stabilisation of CLEC-2 dimers (17, 59, 60). Binding of SFK to 
phosphorylated hemITAM also lead to the complete SFK activation, which additionally amplified Syk 
activation (17, 59). Syk activated T-cell ubiquitin ligand-2 (TULA-2), which is a negative regulator Syk 
activation (44). Active Syk and SFK phosphorylated an adaptor molecule called linker adapter for T-cells 
(LAT) leading to LAT-signalosome formation (34, 40, 61), which consists of PLCγ2, phosphoinositide-3-
kinase (PI3K), SH2 domain-containing leukocyte phosphoprotein of 76kDa (SLP-76) and a set of other 
adaptor proteins. In the LAT-signalosome the PI3K became active and produced phosphoinositol-3,4,5 
trisphosphate (PIP3) from phosphoinositol-4,5 bisphosphate (PIP2) in the surrounding plasma membrane 
region. The increase in PIP3 concentration resulted in Bruton’s tyrosine kinase (Btk) attraction to the 
region and phosphorylation and activation of PLCγ2 (62). Finally, PLCγ2 hydrolysed PIP2 and produced 
inositol-1,4,5 trisphosphate (IP3). IP3 induced Ca2+ signalling. A brief scheme of platelet CLEC-2 signalling 
(Fig. 1) described above was the basis of the constructed computational model. 
3.2. Computational model construction 
The computational model of CLEC-2 induced platelet activation was designed according to the scheme 
above. It consisted of 5 compartments: extracellular space, plasma membrane, cytosol, DTS membrane 
and DTS (Table S1). The model included the following biochemical modules: “CLEC-2 clustering” module, 
capturing CLEC-2 ligand binding and cluster formation (Tables S2-S4, Fig. 2A); “Quiescent state” module, 
capturing CD148 and C-terminal Src kinase (Csk) mediated SFK activation and Syk primary activation by 
active SFKs (Table S5, S6, Fig. 2B); “Tyrosine kinase” module, capturing CLEC-2 phosphorylation and 
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activation of Syk and SFK kinases (Tables S5, S6, Fig. 2C); “LAT-PLCγ2” module, capturing events 
downstream of activated Syk and SFK including phosphorylation of LAT, PI3K and Btk incorporation to 
the signalosome, PLCγ2 activation and production of IP3 (Tables S7, S8, Fig. 2D); “Calcium” module, 
capturing IP3 induced calcium signalling in platelet cytosol (from (45, 63), Fig. 2D). The underlying 
systems of differential equations were constructed from current biological knowledge (see above) using 
the assumptions of either mass action or Henry-Michaelis-Menten kinetics. The probabilities in the 
corresponding stochastic model were calculated based on the same assumptions. The parameter values 
were taken from the experimental reports on the corresponding human enzymes, while the numbers of 
proteins per platelet were taken from the published proteomics data (64). The model reactions, 
equations and parameter values can be found in Supporting Information. 
The “CLEC-2 clustering” module described the process of receptor clustering. Mathematically this 
description was performed by two differential equations, based on our previously published study (65). 
This approach was called the “2-equation” model (Fig. 2A). Its applicability and correspondence to an 
explicit model of receptor cluster formation (called “N-equation” model) and experimental data are 
given in the Supporting Information (Fig. S1). The “2-equation” model described the behaviour of 
variables for the concentration of single CLEC-2 molecules and the concentration of CLEC-2 clusters in 
the plasma membrane (Fig. 2A, S1B). During the estimation of the “CLEC-2 clustering” module 
parameters, we identified two distinct patterns of receptor clustering in the “2-equation” model. The 
first, which could be called “ligand-mediated” cluster formation, suggested that the clustering coincides 
with receptor ligation. The second, called the “post-ligation” cluster formation, suggested that the 
clusters appear after the formation of receptor-ligand complexes. Both patterns will be discussed 
further in section 3.3. All of the model calculations were performed with “ligand-mediated” cluster 
formation model, except where otherwise stated.  
For the “Quiescent state” module, the unknown parameters were tuned to obtain 5% of active Syk 
kinases and 10% of active SFK kinases at the steady-state achieved without CLEC-2 ligand in the system. 
The CD148 phosphatase and Csk kinase were introduced into the model to maintain this steady-state 
(Fig. 2B). For the “Tyrosine kinase” module, we assumed that the first event was the phosphorylation of 
CLEC-2 in clusters by Syk kinases. The activation of Syk kinases, as well as SFK activation, was assumed to 
occur depending on the CLEC-2 cluster size. The descriptions of the “LAT-PLCγ2” module and the 
“Calcium” module can be found in the Supporting Information (Fig. 2D). It is noteworthy that the only 
link between the “Calcium” module and the other modules was the IP3 concentration, which in its turn 
was mediated by active PLCγ2. That is why we chose the number of active PLCγ2 as one of the major 
model output. A network diagram depicting all of the reactions and parameters of the model is given in 
Fig. S2. The corresponding SBML files can be found in the online Supporting Information (also see Table 
S9 for details). 
The full model was constructed as a sum of the separate models described above without further 
adjustment of the parameters. The full model appeared to be capable of the correct description of the 
following experimental data. The predicted numbers of active Syk, SFK and the phosphorylated LAT (Fig. 
2E, S3, 2F, respectively) were in good agreement with available from experimental literature data (21). 
However, the predicted numbers of active PLCγ2 described the data less accurately (Fig. 2G), which 
could be caused by the secondary activation of platelets under the conditions of the experiment.  
3.3. Two different clustering patterns predicted by the model  
In the process of parameter estimation for “CLEC-2 clustering” module, we identified two different 
possible sets of parameters, with which the model could describe experimental data from (38) (Fig. 3, 
S1D). The first observed pattern was called a “ligand-mediated” receptor clustering when the rapid 
receptor dimerisation immediately followed the receptors’ ligation (Fig. 3A). The “ligand-mediated” 
receptor clustering mode corresponds to the ligand-driven receptor clustering mechanism in vivo. The 
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second pattern, when the receptors’ ligation did not directly lead to receptor dimerisation, was termed 
“post-ligation” (Fig. 3A). This mode corresponded to the assumption that CLEC-2 receptor undergoes 
additional conformational changes after ligation, which made it more prone to clustering. The 
comparison of the average cluster size between two different schemes is given in Figure 3B. Parameter 
variation results revealed that the maximum size of the CLEC-2 clusters is determined by the total 
number of CLEC-2 as well as kinetic parameters of the clustering, both for “ligand-mediated” (Fig. S4A-C) 
and “post-ligation” (Fig. S4G-L) clustering regimes. However, in the “ligand-mediated” clustering regime, 
maximum CLEC-2 cluster size appeared to be more sensitive to the assessed parameters, than in the 
“post-ligation” regime. (Fig. S4). 
With both schemes, the full model predicted cytosolic calcium spiking (Fig. 3A). However, the “post-
ligation” scheme could not be tuned to induce calcium spiking earlier than 200s after ligand introduction 
(Fig. 3A,D), despite producing a more significant increase in the number of active PLCγ2 (Fig. 3C) and 
higher concentration of cytosolic calcium in the cell population (Fig. 3D). However, previous 
experimental data (21) suggested much shorter activation times for CLEC-2 induced platelet activation, 
and thus, we preferred the “ligation-mediated” scheme. Curiously, a rapid dimerisation of ITAM 
receptors was demonstrated to correlate with the shortened cell activation lag-times elsewhere (41).  
3.4. Sensitivity analysis of the model 
To analyse the influence of unknown parameters and determine the possible rate-limiting steps, we 
performed a local sensitivity analysis (Fig. 4, S5-S16). Scaled local sensitivities of the time to reach the 
peak quantities/concentrations of active Syk ( ), phosphorylated LAT ( ), active PLCγ2 ( ), IP3 ( ), 
and cytosolic Ca2+ to all model parameter values were calculated. The results are given in Figures 4A and 
S5. Parameters of the “Tyrosine kinase” module had the biggest impact on all of the analysed variables. 
The “LAT-PLCγ2” module parameters were less influential and “CLEC-2 clustering” module parameters 
were the least influential. “Tyrosine kinase” module parameters concerning Syk ([Syk]0, , , 
and ) influenced all platelet responses, while its parameter for CLEC-2 dephosphorylation rate 
( ) was the most influential only for  (active Syk). Among “LAT-PLCγ2” module, the most 
influential parameters were the reverse rate of LAT phosphorylation and LAT concentration ( , 
[LAT]0 for all of the variables, except Syk) and the catalytic parameters of Btk kinase ( , , for all 
variables except Btk). Finally, among parameters of the “CLEC-2 clustering” module , ,  
alongside CLEC-2 initial concentration were influential for all responses. Explicit variation of the most 
influential model parameters for PLCγ2 is given in Figure 4B–M. Variation of the rest of parameters 
concerning all of the analysed variables and sensitivity scores for all of the variables can be found in 
Supporting Information (Fig. S6 – S16, Tables S10 – S14, correspondingly). Based on these results we can 
conclude that the most influential parameters for all of the analysed variables concern Syk kinase 
activation ( , , ). On the other hand, parameters, governing reverse reactions ( , 
, ) as well as parameters concerning TULA-2 activation ( , , ) also 
were among the most influential, which highlights the role of the negative regulators of signalling for 
CLEC-2 induced platelet activation. Finally, local sensitivity analysis also allowed to identify three rate-
limiting reactions: Syk kinase activation, LAT phosphorylation and CLEC-2 cluster formation. Among 
these reactions, Syk activation was the most influential.  
3.5. CLEC-2 agonist fucoidan is capable of evoking calcium response in platelets independently from 
secondary mediators of signalling 
One of the model predictions suggested that CLEC-2 stimulation was sufficient to initiate calcium 
signalling in platelets (Fig. 3A, D). To test this prediction, we performed flow cytometry experiments on 
platelets loaded with calcium fluorophore Fura Red (Fig. 5A). To avoid an impact of secondary activation, 
we pre-incubated platelets with P2Y1 receptor antagonist MRS2179 (Fig. 5A). To assess the predicted 
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dependence of platelet activation on the clustering of CLEC-2, we investigated the influence of 
membrane cholesterol content on calcium response. Cholesterol molecules determine the stability of 
membrane regions, and thus incubation od cells with a cholesterol-binding agent mβCD could disrupt 
clusters of proteins (51). During experiments, we observed that while high concentrations (5 mM) of 
mβCD were capable of severe disruption of platelet response to fucoidan (Fig. 5B), relatively low 
concentrations of mβCD (1 mM) delayed platelet activation not affecting its degree (Fig. 5B). This 
observation was in agreement with model predictions (Fig. 3D), supporting rapid clustering pattern for 
CLEC-2 (Fig. 3A). To test the prediction of the model that fucoidan induces rare calcium spiking in 
platelets instead of a stationary increase in calcium concentration (Fig. 3A), we performed analysis of 
single-cell calcium signalling using fluorescence microscopy (Fig. 5C,D). Washed Fura Red loaded 
platelets spread on fucoidan covered glass (Fig. 5C) which resulted in prolonged calcium spiking (Fig. 
5D). This observation supported the model prediction that fucoidan is capable of calcium spiking 
induction.  
3.6. Impact of the medium temperature and plasma membrane fluidity on CLEC-2 induced calcium 
response in platelet suspension 
We have performed further investigation of fucoidan-induced intracellular signalling in platelets in the 
presence of mβCD and temperature variation to test the model predictions on the role of the receptor 
clustering process. At both room (25oC) and body (37oC) temperature, activation of platelets with 
fucoidan lead to an increase in cytosolic Ca2+ concentration (Fig. 6A). However, at 25oC this increase 
occurred at 100 s, while at 37 oC it was significantly more rapid and occurred at 60 s. Pre-incubation of 
platelets with mβCD further delayed the increase in the concentration of cytosolic calcium both at 25 oC 
(240 s) and at 37 oC (105 s) (Fig. 6B). It should be noted that temperature variation did not affect the 
activation of platelets by low concentrations (2 μM) of ADP (Fig. S17). 
Single-cell analysis by means of immunofluorescent microscopy revealed that at 37oC clustered fractions 
of phosphorylated LAT, which are known markers of cholesterol-enriched microdomains in platelet 
membrane (34), appeared at the 30s and the amount of phosphorylated LAT reached its maximal values 
by 60s (Fig. 6C, S18). It is noteworthy that at most timepoints the bright LATp fluorescence spots could 
be observed. The lower medium temperature and cholesterol depletion by 1 mM mβCD resulted in 
delayed LATp phosphorylation and decreased clustering (Fig. S19, S20, correspondingly). Platelets 
activated by CRP exhibited the most significant increase in LATp phosphorylation after 300s (Fig. S21). 
The “CLEC-2 clustering” module parameter variation (k1 and k3 decrease and k-2 increase) allowed to 
accurately describe the decrease in LAT phosphorylation upon temperature lowering and cholesterol 
depletion (Fig. 6C, Table S15). 
To investigate which part of the CLEC-2 signalling cascade is influenced by the temperature changes, we 
performed immunoblotting analysis of tyrosine phosphorylation level in platelets activated by fucoidan 
at room and body temperature (Fig. 6D-G). Washed human platelets at concentration 1.5 109/ml in 
modified Tyrode’s buffer (no BSA and no Ca2+) were incubated with fucoidan for 0-5m at given 
temperature conditions. Samples were taken at 15-30 s time intervals and analysed by immunoblotting 
with anti-phospho-tyrosine antibody PY20 as described in the Methods section. The analysis shows that 
while 1 μg/ml of fucoidan does not induce significant activation. On the other hand, both 10 and 100 
μg/ml of fucoidan induced tyrosine phosphorylation with peak values at 90 s and 30 s respectively. The 
increase in temperature significantly shortened the lag-times of phosphorylation to 60 s and 15 s 
respectively. Thus we can conclude that the temperature variation influence activity of tyrosine kinases 
as well as calcium signalling. This result is in agreement with the model prediction that the rate of CLEC-
2 clustering determines the time-lapse to peak platelet activation. 
3.7. Impact of the medium temperature on CLEC-2 induced calcium response in single cells 
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TIRF-microscopy of immobilised single calcium-sensitive dye loaded platelets was performed, to 
investigate the nature of the cytosolic calcium increase observed in flow cytometry. We utilised two 
experimental settings. In the first setting, platelets were immobilised on VM64 (anti-CD31 clone (48)) 
antibody (Fig. 7A-D), and fucoidan solution in Tyrode’s buffer was washed over the surface. Platelets 
developed cytosolic calcium spiking with varying intensity (Fig. 7A, C). Frequent cytosolic calcium spiking 
intensified by 50s after fucoidan addition (Fig. 7A-D). Maximal calcium concentration in the spikes, as 
well as spike frequency corresponded with the model predictions (Fig. 5A). Comparison between 
fucoidan-induced calcium spiking between 25oC (Fig. 7A) and 37oC (Fig. 7C) shows that the frequency of 
spiking increases at body temperature and there is also a noticable increase in amplitude. This result 
corresponds to the prediction that fucoidan-induced platelet activation could be influenced by the 
temperature-dependent parameters: receptor translocation and enzyme turnover rates. Together these 
data corroborate the model predictions that a) fucoidan induces calcium spiking in platelets and b) 
fucoidan-induced activation of platelets is significantly influenced by temperature. It could be noticed 
that while the amplitudes of the calcium spikes remained around the same values at different 
temperatures (Fig. 7F), the interspike time intervals were significantly shorter at 37oC than at 25oC (Fig. 
7E). This observation corresponded with the model prediction that an increase in CLEC-2 clustering rates 
in the membrane lead to an increase in cytosolic calcium spiking (Fig. S22). 
4. Discussion 
Here we aimed at investigation of primary regulatory mechanisms of platelet CLEC-2 induced activation 
by means of comprehensive computational systems biology modelling. Our model accurately 
reproduced literature data on platelet activation by CLEC-2 agonists fucoidan, rhodocytin and 
podoplanin. The model gave a set of predictions. First, a rapid CLEC-2 clustering upon ligation was 
required for platelet activation by CLEC-2 agonists, which corresponded to data from (41) and our 
experiments with mβCD treated platelets (Fig. 5B). Second, CLEC-2 ligands are capable of inducing 
cytosolic calcium spiking independent on platelet secondary activation, which corresponded to data 
from (40) and our experiments with MRS2179 (Fig. 5A, 6A, B). Third, the sensitivity analysis of the model 
has revealed a key role of Syk kinases in the CLEC-2 signalling cascade (Fig. 3), which was in perfect 
agreement with (17, 56). Finally, the CLEC-2 clustering and LAT-signalosome formation appeared to be 
the rate-limiting steps in signal propagation in addition to tyrosine kinase activities. This proposition was 
supported by our experiments at different temperature conditions alongside different mβCD 
concentrations (Fig. 6, 7). 
During model development, we applied mathematical equations from our previously published model of 
platelet aggregation (65) to describe the process of receptor clustering (“2-equation” model, Fig. S1B). 
The “2-equation” model described experimental data on CLEC-2 receptor clustering, as well as the 
computational results of a more conventional model of receptor clustering (“N-equation” model, Fig. 
S1A). Two possible receptor clustering patterns distinctive in the sequence of dimerisation and ligation 
of receptors were identified. However, only the inclusion of the pattern with rapid dimerisation in the 
model allowed it to reproduce experimentally observed calcium response (Fig. 3C, D). “The “Ligand-
mediated receptor dimerisation” clustering pattern was in line with experimental data describing the 
capability of the CLEC-2 ligand to promote receptor clustering (35–37). Furthermore, this result was in 
agreement with previously published data on other ITAM-bearing receptors (41). On the other hand, 
CLEC-2 clustering upon activation by monomeric ligands (e.g. podoplanin) has been reported (38), which 
should correspond to “post-ligation” clustering, assuming conformational changes in the CLEC-2 
structure upon ligation. 
The analysis of the model predicted a central role of the Syk tyrosine kinase for CLEC-2 signalling 
cascade (Fig. 4A). This prediction corresponded to previously published data on CLEC-2 stimulation in 
platelets pre-treated with PRT-060318 (57) as well as CLEC-2 stimulation of platelets of mice deficient on 
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Syk activatory SH-2 domains (17). Sensitivity analysis has also revealed that, in addition to the tyrosine 
kinase activity, the PLCγ2 activity and receptor clustering, to a lesser extent, are the rate-limiting steps 
as well (Fig. 4). It is noteworthy that the parameters concerning dephosphorylation of signalling were as 
influential as the parameters concerning the activation of kinases (Fig. 4, S5). This result emphasises the 
role of the negative regulators of intracellular signalling for CLEC-2 induced platelet activation. 
More accurate analysis of the parts of the platelet response influenced by the parameters revealed that, 
although the activity of tyrosine kinases had the most impact on every response, only CLEC-2 clustering 
influenced the time-lapse to peak concentration, while only moderately affecting the number of active 
signalling proteins. This observation was supported by the decrease in platelet activation time with 
temperature increase or mβCD supplementation (Fig. 6A, B). A similar effect could be expected from 
GPVI signalling, which also requires clustering of receptors. Indeed, when GPVI cluster formation was 
affected by losartan, a delay in platelet response to collagen appeared (66). 
In order to test the model predictions that CLEC-2 clustering is one of the rate-limiting processes for the 
CLEC-2 signalling cascade, we investigated the influence of two membrane fluidity changing agents on 
platelet activation. First, we utilised incubation of platelets with a cholesterol-binding agent mβCD, 
which changes membrane cholesterol saturation and thus directly increases the fluidity of the 
membranes. We observed a faster platelet response to CLEC-2 agonists in the presence of mβCD (Fig. 
5B, Fig. 6B). However, these results were in disagreement with previously published work (61), where 
CLEC-2 signalling was shown to be independent of lipid rafts, and lipid raft role was proposed mainly for 
secondary signalling. On the other hand, in (61) platelets were incubated with mCD for an hour and 
this could have led to the reintroduction of cholesterol in the signalling region (67). The dose-dependent 
response to mCD, obtained upon incubation for 15 minutes in our work (Fig. S3B) proves the 
membrane fluidity to be of significance for primary CLEC-2 response.  
The second way to influence the rate of CLEC-2 clustering utilised here was a variation in the 
environment temperature. The temperature decrease from 37oC to 25oC resulted in a prolonged delay 
after activation (Fig. 6, Fig. 7). This result could not be considered as a direct confirmation of the 
receptor clustering impact, as it is well known that the temperature affects the turnover numbers of 
enzymes (68, 69) to the same degree as the rates of diffusion (70, 71). Experimental data on 
immunofluorescence microscopy additionally demonstrated impairment of LAT-signalosome formation 
upon temperature decrease and cholesterol depletion (Fig. 6C, Fig. S18-S20). Based on the model 
predictions, this is justified by the alterations in the receptor cluster formation at different conditions 
(Fig. 6C). Furthermore, the fact that the applied decrease in temperature did not affect the degree of 
activation is in agreement with the model prediction that the receptor clustering affects only the times 
of activation, while the tyrosine kinase activity controls both the time and the degree of activation (Fig. 
4B-E, S8). Additionally, we demonstrated that such temperature variation has no significant effect on 
ADP-induced platelet activation, confirming the hypothesis that receptor clustering is specifically 
important for tyrosine kinase signalling (Fig. S17). 
Among the main features of the model was its capability to work both in stochastic and in deterministic 
modes. Applicability of stochastic modelling to platelets is based on the fact that even at maximal 
degrees of activation upon CLEC-2 stimulation, amounts of crucial signalling proteins do not exceed 200 
(Syk, LAT, PLCγ2).  
Although the experimental data supported our model predictions, some limitations should be noted. 
While it has been shown that fucoidan is capable of activating platelet CLEC-2 (21), it has been 
demonstrated recently, that fucoidan might be activating GPVI and platelet endothelial aggregation 
receptor 1 (PEAR-1) as well (72, 73). However, PEAR-1 and GPVI participation in fucoidan induced 
platelet activation has been demonstrated by aggregometry (72), where the effects of secondary 
mediators of signalling are prevailing (34). Authors of (72) also report that fucoidan is not inducing 
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calcium signalling in platelets solely by implicating spectrofluorimetry, which is insensitive to weak 
calcium signalling.  
The confirmations of model predictions here are limited to experiments with isolated platelets. A large 
part of the model predictions is concerned with kinase activity, not routinely assessed for single cells. 
For the experiments with immunoblotting, the distinction between primary and secondary signalling for 
tyrosine phosphorylation assays is not evident. Additional experiments on the roles of tyrosine kinases 
in CLEC-2 signalling as well as further model development (direct inclusion of the protein-tyrosine 
phosphatase 1B (PTP1B) phosphatase) and investigation of cooperativity between CLEC-2 and GPVI 
should be the subject of further studies. 
The fact that the motion of proteins drives CLEC-2 activation in the plasma membrane and the assembly 
of signalling complexes demonstrated here allows us to take a new perspective on all receptors that 
perform clustering after activation or are associated with specific lipid micro-domains. The knowledge of 
the underlying mechanisms of receptor cluster assembly will push forward understanding of molecular 
signalling in all types of the eukaryotic cell as well as developing of new antithrombotic agents, 
specifically targeting receptor cluster formation. 
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Figure 1. CLEC-2 induced signalling in blood platelets. In resting platelets, relatively few Syk kinases are active due 
to low SFK activity. Upon ligation of the platelet CLEC-2, and CLEC-2 cluster formation, tyrosine residues in the 
CLEC-2 cytoplasmic domain (YxxL sequence, hemITAM) become phosphorylated by Syk kinases. Non-active Syk 
bind to phosphorylated hemITAM with its SH2 domains and become active via trans-autophosphorylation. 
Accumulation of the active Syk results in downstream platelet activation and calcium signalling.  
Figure 2. Scheme of the model of platelet CLEC-2 signalling. “CLEC-2 clustering” module (A): after CLEC-2 ligation 
CLEC-2 molecules to formed clusters. Model of the CLEC-2 clustering is based on (65). Activated CLEC-2 molecules 
could form CLEC-2 clusters, which could form larger clusters by binding single activated CLEC-2 molecules or other 
clusters. Clusters decayed into cluster and cluster or cluster and single CLEC-2 molecule. “Quiescent state” module 
(B): active CD148 produces 1/3 active SFK, which are negatively regulated by active Csk. 1/3 active SFK auto-
phosphorylated and became 2/3 active SFK. Active CD148 negatively regulated this reaction. All forms of active SFK  
mediated CD148, Csk and Syk activation. Active Syk activated non-active Syk. “Tyrosine kinase” module (C): after 
cluster formation, active Syk phosphorylated hemITAM in the CLEC-2 cytoplasmic domains. Inactive Syk or 2/3 
active SFK bound phospho-hemITAMs (two for Syk and one for SFK) with their SH2 domains and became active. 
Active Syk also mediated TULA-2 phosphatase activation, which is a negative regulator of Syk activity. “LAT-PLCγ2” 
module (D): active Syk phosphorylated the adaptor protein LAT. PLCɣ2 and PI3K bound P-LAT, which activated 
PI3K. Active PI3K phosphorylated PIP2 and produced PIP3, which became a docking site for Btk. Btk activated upon 
PIP3 binding and activated PLCɣ2. Active PLCɣ2 hydrolysed PIP2 and produced IP3. “Calcium” module (D): IP3 
activated IP3R on the surface of the DTS. Through active IP3R free Ca2+ ions passed to the cytosol. Ca2+ inhibited 
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IP3R as well and returned to the DTS via SERCA. Dark blue lines represented transitions between species; light blue 
lines represent catalysis. Copy numbers of active Syk (E), LAT (F) and PLCγ2 (G) were fitted to experimental data on 
fucoidan induced platelet activation from (21). 
Figure 3. Comparison of the receptor clustering patterns effects on platelet CLEC-2 induced activation. Two 
patterns of receptor clustering – ligand-mediated receptor clustering (rapid receptor dimerisation upon ligation – 
black) and post-ligation clustering (ligation does not lead to rapid receptor dimerisation – red) - A. Both 
approaches resulted in cytosolic calcium spiking. However, post-ligation model resulted in a significantly delayed 
activation in comparison to rapid-dimerisation model (C). Averaging of the calcium concentration over 500 
stochastic runs of the model also demonstrated that delayed model demonstrated significantly delayed, but yet 
amplified response in comparison to rapid-dimerisation model (D).  
Figure 4. Sensitivity analysis and variation of the unknown parameters. Sensitivity scores for the effect of 
parameter variation on the concentration of active PLCγ2 were calculated (A). Explicit variation of the parameters 
with the highest sensitivity scores for the effect on maximal PLCγ2 number and time to reach maximum: CLEC-2 
clustering k-2 (B), CLEC-2 clustering k-1 (C), CLEC-2 clustering k3 (D), CLEC-2 initial number (E), turnover rate of Syk 
kinases (F), Michaelis constant of Syk kinases (G), forward rate of Syk activation upon SH-2 domain binding to 
dually phosphorylated hemITAMs (H), Syk initial number (I), reverse rate of LAT phosphorylation (J), turnover rate 
of Btk (K), Michaelis constant of Btk (L), LAT initial number (M). 
Figure 5. CLEC-2-evoked calcium signalling in platelets. Continuous flow cytometry analysis of highly diluted 
platelet suspension (1x103 plt/ml) revealed that CLEC-2 agonist fucoidan induced calcium response is independent 
of the presence of MRS2179 (A) while being gradually dependent on the concentration of mβCD (B). Single-cell 
analysis using TIRF-microscopy revealed that platelets are capable of spreading on fucoidan-covered glass (C) and 
that immobilised fucoidan is capable of evoking calcium oscillations in platelets (D).  
Figure 6. Platelet CLEC-2 signalling is dependent on temperature conditions. Flow cytometry assay of CLEC-2 
induced signalling in platelets after activation by 100 μg/ml of fucoidan. Activation at 25oC was significantly slower 
than at 37oC (A). Disruption of lipid rafts by mβCD delayed activation (B). Each curve represents data from at least 
three experiments. (C) Comparison of the immunofluorescent assays with computational model predictions 
describing the dependence of platelet CLEC-2 induced activation from medium temperature and cholesterol 
presence in the cell membrane. Each experimental time-point is averaged over 50 platelets. (D-G) Immunoblot 
assay of CLEC-2 induced signalling (D – raw data): platelets were activated by 1(E)-10(G)-100(F) μg/ml of fucoidan 
at 25oC or 37oC. Samples for analysis were taken 0-15-30-60-90-120-150-180-300 s after activation. Murine anti-
human-phosphotyrosine primary anti-bodies (PY-20 clone) were used. Anti-tubulin primary antibodies were used 
as loading control after stripping. A typical experiment for one out of n = 3 different donors. 
Figure 7. Cytosolic calcium spiking induced by fucoidan in single cells. Platelets were loaded with Fura-2, 
immobilised on VM-64 (A-D) and then illuminated by 405 nm laser. Cytosolic calcium concentration was 
recalculated from Fura-2 fluorescence (see Methods). Washed platelets were immobilised on VM64 antibody (A-
D). At time-point “0” fucoidan solution at 100 μg/ml was added. Cytosolic calcium spiking (A, C) and whole-cell 
fluorescence (B, D) were monitored at room temperature (A, B) or 37 oC (C, D). Representative curves out of n=10. 
I, J – Intervals between calcium spikes (E) and calcium concentration per spike (F), spread on VM-64 and activated 
by fucoidan at 25oC (black) or 37oC (red). Data collected from 20 cells. 
